Over the past few months, the Biden administration has singled out Covid therapeutics, including the antiviral pill Paxlovid, as a core part of its strategy to fight the coronavirus pandemic, but there’s evidence some Americans haven’t. easy access to treatment or are not seeking it.
The New York Times is interested in hearing from people about their experiences trying to get Paxlovid and other therapies (including monoclonal antibodies and Lagevrio) as well as those who have avoided these treatments. Was it easy to get the pills? Did you run into any obstacles? Did you have difficulty proving that you were eligible for treatment? Or have you avoided Paxlovid or other treatments for some reason?
Please answer the questions below. A Times reporter or editor may contact you to learn more about your story. We will not publish your name without your permission.